| Price | 530.00p on 26-10-2026 at 19:35:06 |
|---|---|
| Change | 5.00p 0.95% |
| Buy | 560.00p |
| Sell | 500.00p |
| Last Trade: | Sell 3.00 at 525.30p |
| Day's Volume: | 3,679 |
| Last Close: | 530.00p |
| Open: | 525.00p |
| ISIN: | GB00BMCLYF79 |
| Day's Range | 525.00p - 530.00p |
| 52wk Range: | 425.00p - 820.00p |
| Market Capitalisation: | £82.07m |
| VWAP: | 544.9028p |
| Shares in Issue: | 15.48m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
4basebio Plc (4BB) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 3 | 525.30p | Ordinary |
15:50:07 - 26-Oct-26 |
| Sell* | 1 | 509.00p | Ordinary |
15:43:19 - 26-Oct-26 |
| Unknown* | 0 | 560.00p | SI Trade |
14:17:11 - 26-Oct-26 |
| Unknown* | 3,668 | 545.00p | Negotiated Trade |
08:03:06 - 26-Oct-26 |
| Sell* | 7 | 507.50p | Ordinary |
08:00:49 - 26-Oct-26 |
| Buy* | 1 | 525.30p | Ordinary |
08:31:12 - 22-Oct-26 |
| Buy* | 98 | 550.00p | Ordinary |
15:58:01 - 21-Oct-26 |
| Buy* | 19 | 526.00p | Ordinary |
08:30:14 - 21-Oct-26 |
| Sell* | 183 | 507.50p | Ordinary |
16:01:33 - 20-Oct-26 |
| Buy* | 18 | 543.30p | Ordinary |
10:34:44 - 20-Oct-26 |
4basebio Plc (4BB) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 21st Oct 2026 3:00 pm | PRN | Result of Retail Offer |
| 20th Oct 2026 7:00 am | PRN | Posting of Circular and Notice of General Meeting |
| 15th Oct 2026 4:00 pm | PRN | Proposed Retail Offer |
| 15th Oct 2026 3:15 pm | PRN | Results of Capital Raise |
| 15th Oct 2026 7:00 am | PRN | Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million |
| 28th Sep 2026 7:01 am | PRN | Half-year Report |
| 28th Sep 2026 7:00 am | PRN | 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program |
| 7th Sep 2026 7:00 am | PRN | 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine |
| 26th Aug 2026 7:00 am | PRN | 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing |
| 22nd Jul 2026 7:00 am | PRN | Grant of Options & Director/PDMR Dealing |
